Targeted Therapy for Early and Locally Advanced Breast Cancer - Wikidata - awgldk - TriplyDB

Targeted Therapy for Early and Locally Advanced Breast Cancer

Targeted Therapy for Early and Locally Advanced Breast Cancer

http://www.wikidata.org/entity/Q34096070

about

Targeted Therapy in Breast Cancer.Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?

P2860

Q34096056-2B86AF9D-E8CB-4CC3-AE6F-A571D9723BCB Q52844847-F450B103-F506-4F8B-AD75-ADAA19E3339E

P2860

Targeted Therapy for Early and Locally Advanced Breast Cancer

http://www.wikidata.org/entity/Q34096070

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeted Therapy for Early and Locally Advanced Breast Cancer

@ast

Targeted Therapy for Early and Locally Advanced Breast Cancer

@en

Targeted Therapy for Early and Locally Advanced Breast Cancer

@nl

type

label

Targeted Therapy for Early and Locally Advanced Breast Cancer

@ast

Targeted Therapy for Early and Locally Advanced Breast Cancer

@en

Targeted Therapy for Early and Locally Advanced Breast Cancer

@nl

prefLabel

Targeted Therapy for Early and Locally Advanced Breast Cancer

@ast

Targeted Therapy for Early and Locally Advanced Breast Cancer

@en

Targeted Therapy for Early and Locally Advanced Breast Cancer

@nl

P1433

Q34096070-60DC0898-559D-4F0D-BE04-A6832073196A

P1476

Q34096070-AB99A593-AB93-4C8F-8A31-4EC182673EE2

P2860

Q34096070-0FC3D6FA-A481-4A0B-AB71-6ED41B94BEFA

Q34096070-16A5E80E-92FB-4416-93CE-4ADC01F28B85

Q34096070-1E3A4A52-F504-46BE-8B97-58BF8AF718C3

Q34096070-31322DB2-3BF1-42B7-B6E3-BC754860621C

Q34096070-466289A0-9C68-4FB1-B9A7-53B681756731

Q34096070-4E6FAE7E-440F-4EFB-AF62-66BC064AEECE

Q34096070-580E9764-E4A9-4EB4-B99A-5606BC3EA0EF

Q34096070-6995B893-1DD0-45AF-B430-3B840C321666

Q34096070-6D943273-8B3F-455D-800B-DB48D1327955

Q34096070-8790FEB8-BF9A-4BA1-BD56-B84C31521BFA

P304

Q34096070-5C878450-ADEB-435E-8DEB-3BDB318EA93C

P31

Q34096070-B219687B-7590-4721-869C-FABF5585A6AE

P356

Q34096070-49E3A134-D7E5-4ABC-AF25-DD53C0528E02

P433

Q34096070-9BC96034-046B-4B2F-B114-C73118390BED

P478

Q34096070-7146A265-EA20-4782-850F-773E5F1381E6

P50

Q34096070-3525DD9E-9DD5-4099-9E3D-6FE90BD8966A

P577

Q34096070-A079CDA0-668B-4F23-93EF-EE7E815140C9

P5875

Q34096070-3E0ABC6F-7987-4527-B066-42176CA5C8BE

P698

Q34096070-6080A031-6E01-4047-9A38-D79D1718DB46

P932

Q34096070-CA1F139D-B859-4E9F-9459-8495182CEFE5

P356

P1433

P1476

Targeted Therapy for Early and Locally Advanced Breast Cancer

@en

P2860

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.

P304

144-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000315047

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46289001

http://www.w3.org/2001/XMLSchema#string

P698

20847827

http://www.w3.org/2001/XMLSchema#string

P932

2931052

http://www.w3.org/2001/XMLSchema#string